Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN®
San Diego, CA & Rotterdam, Netherlands- February 19, 2026 — SkylineDx today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its…
Breaking News
02/19/2026
Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN®
San Diego, CA & Rotterdam, Netherlands- February 19, 2026 — SkylineDx today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its…
|
|
02/05/2026
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate SAN CARLOS, Calif., Feb.…
|
|
10/22/2025
SkylineDx Publishes Landmark MERLIN_001 Trial in JAMA Surgery Validating the Predictive Power of the Merlin CP-GEP Test in Melanoma
Rotterdam, The Netherlands – San Diego, CA – [October 22nd] – SkylineDx today announced that results from its landmark MERLIN_001…
|
|
10/20/2025
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026 WOBURN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) — Replimune…
|
08/12/2025
Remembering Brandon Blackstock: A Call to Action on Melanoma Awareness
Difficult News and A Reminder of the Impact of Melanoma Today we would like to acknowledge the recent death of…
|
08/11/2025
IO Biotech Announces Phase 3 Results for Cylembio® + KEYTRUDA® in Advanced Melanoma
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT) today announces topline results from the pivotal Phase…
|
|
07/25/2025
The FDA Said No — Now We Need Your Voice
Dear Friends, A recent FDA decision denied approval of a promising new treatment called RP1 for advanced melanoma—one that showed…
|
|
05/28/2025
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications
News provided byHalozyme Therapeutics, Inc. May 28, 2025, 08:30 ET Opdivo® is the first and only PD-1 inhibitor approved for subcutaneous (SC)…
|
|
01/21/2025
Replimune Announces BLA Acceptance and Priority Review for RP1 for the Treatment in Advanced Melanoma
PDUFA action date of July 22, 2025, with priority review January 21, 2025 08:00 ET| Source: Replimune Group Inc WOBURN,…
|
12/30/2024
Jimmy Carter: A Life that Shaped Cancer Treatment and Hope for Melanoma Patients
Former U.S. President Jimmy Carter, who passed away on December 29, 2024, at the age of 100, will be remembered…
|
Recent Posts
Feb. 19, 2026
Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN®
Feb. 05, 2026
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
Jan. 23, 2026
Moderna, Merck’s Skin Cancer Vaccine Shows Sustained Benefit in Five-Year Follow-Up
Jan. 21, 2026
Reflecting on Melanoma Treatment in 2025 and Looking to the Future in 2026
Jan. 13, 2026